Steven Pearson, ICER president (Adrien Villez for Endpoints News)
July 13, 2023 12:27 PM EDTUpdated 05:17 PM
Pharma

ICER re­vis­es sick­le cell gene ther­a­py re­port, preps to dig in­to what CMS ne­go­ti­a­tions might look like

Zachary Brennan

Senior Editor

The Boston-based In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, a drug price watch­dog, has re­vised its re­port on sick­le cell gene ther­a­pies and is plan­ning a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times